CD4 and infection: Similar to the re-infection experiment (Fig. 3b), we found that mice receiving CD4 T cells from celecoxib-treated animals had a higher lung bacterial burden at week 6 of the infection, indicating that the long-term protective capacity of the CD4 T cells was compromised by the celecoxib treatment (Fig. 4g).